ClinicalTrials.gg
Not yet recruitingNCT07391033PICCOLETO-XIUpdated Feb 5, 2026

The PICCOLETO XI A-PREP Study

An observational study in In-Stent Coronary Artery Restenosis and Coronary Artery Disease, sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

To compare the angiographic and clinical outcomes of aggressive versus standard balloon preparation during drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR). The study will evaluate whether more aggressive lesion preparation with cutting/scoring/OPN balloons improves outcomes compared to standard preparation with semi-compliant or non-compliant balloons.

Read the detailed description

PICCOLETO XI A-PREP is an investigator-initiated, multicenter, international, observational study evaluating the impact of lesion preparation strategies on outcomes following drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR).

In-stent restenosis remains a clinically relevant challenge despite advances in drug-eluting stent technology and contemporary percutaneous coronary intervention techniques. DCB represents a stentless therapeutic strategy for ISR treatment, with the advantage of avoiding implantation of additional metallic layers.

A key determinant of clinical outcomes in ISR, particularly with DCB angioplasty, is the adequacy of lesion preparation before definitive therapy. Effective preparation facilitates optimal drug delivery, improves luminal gain, and may reduce the risk of recurrent restenosis.

A large spectrum of balloon-based modalities is available for ISR lesion preparation, ranging from semi-compliant and non-compliant balloons to more aggressive tools such as scoring and cutting balloons. Although more aggressive devices may enhance plaque modification and neointimal tissue disruption, their incremental clinical benefit over standard approaches remains uncertain.

Patients will be categorized into two groups based on lesion preparation strategy:

  • Aggressive preparation: Cutting/Wolverine balloons, scoring balloons (any brand), and/or OPN balloons
  • Standard preparation: Semi-compliant balloons and/or non-compliant balloons

Clinical outcomes will be assessed at 1-year and longest available follow-up.

02

Conditions studied

  • In-Stent Coronary Artery Restenosis
  • Coronary Artery Disease

Keywords

  • Drug-Coated Balloon
  • In-Stent Restenosis
  • Lesion Preparation
  • Cutting Balloon
  • Scoring Balloon
  • Percutaneous Coronary Intervention
03

In context

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

This study's planned enrollment of 500 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Fondazione Ricerca e Innovazione Cardiovascolare ETS is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients who underwent drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR) at participating centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥18 years of age
  • Patients who underwent DCB angioplasty for in-stent restenosis

Exclusion criteria

Exclusion Criteria:

- Lack of clinical outcome assessment

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Aggressive Lesion Preparation

    Patients who underwent lesion preparation using cutting/Wolverine balloons, scoring balloons (any brand), and/or OPN balloons prior to DCB angioplasty for ISR.

  • Standard Lesion Preparation

    Patients who underwent lesion preparation using semi-compliant balloons and/or non-compliant balloons prior to DCB angioplasty for ISR.

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular Events (MACE)

    Composite of cardiac death, non-fatal myocardial infarction (MI), or target lesion revascularization (TLR).

    Time frame: 12 months

Secondary outcomes

  1. Cardiac Death

    Death attributed to cardiovascular causes, including death from unknown cause.

    Time frame: 12 months and longest available follow-up

  2. Non-fatal Myocardial Infarction

    Non-fatal myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction.

    Time frame: 12 months and longest available follow-up

  3. Target Lesion Revascularization (TLR)

    Any repeat revascularization (percutaneous or surgical) of the target lesion.

    Time frame: 12 months and longest available follow-up

  4. Target Vessel Myocardial Infarction (TV-MI)

    Myocardial infarction attributable to the target vessel based on clinical, electrocardiographic, and biomarker criteria.

    Time frame: 12 months and longest available follow-up

  5. BARC Major Bleeding

    Bleeding Academic Research Consortium (BARC) major bleeding events (type 3-5).

    Time frame: 12 months and longest available follow-up

  6. Procedural Success

    Successful DCB angioplasty with residual stenosis less than 30% and TIMI flow grade 3 without major procedural complications.

    Time frame: At procedure

  7. Post-procedural Diameter Stenosis

    Percentage of diameter stenosis after DCB angioplasty assessed by quantitative coronary angiography.

    Time frame: At procedure

  8. Angiographic Dissection

    Presence and type of coronary dissection after lesion preparation and DCB treatment.

    Time frame: At procedure

  9. TIMI Flow Grade

    Thrombolysis In Myocardial Infarction (TIMI) flow grade assessment post-procedure.

    Time frame: At procedure

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Wanha W, Iwanczyk S, Tajstra M, Cortese B. How to treat coronary in-stent restenosis? Recent advances and their practical implications: State-of-the-Art Review. Kardiol Pol. 2025;83(5):556-569. doi: 10.33963/v.phj.105954. Epub 2025 May 14. PubMed 40365890 ↗
  • Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010 Nov 30;56(23):1897-907. doi: 10.1016/j.jacc.2010.07.028. PubMed 21109112 ↗
  • Latib A, Mussardo M, Ielasi A, Tarsia G, Godino C, Al-Lamee R, Chieffo A, Airoldi F, Carlino M, Montorfano M, Colombo A. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. JACC Cardiovasc Interv. 2011 Feb;4(2):155-64. doi: 10.1016/j.jcin.2010.09.027. PubMed 21349453 ↗
  • Mauri L, Bonan R, Weiner BH, Legrand V, Bassand JP, Popma JJ, Niemyski P, Prpic R, Ho KK, Chauhan MS, Cutlip DE, Bertrand OF, Kuntz RE. Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002 Nov 15;90(10):1079-83. doi: 10.1016/s0002-9149(02)02773-x. PubMed 12423707 ↗
  • Bonaventura K, Schwefer M, Yusof AKM, Waliszewski M, Krackhardt F, Steen P, Ocaranza R, Zuhdi AS, Bang LH, Graf K, Bock U, Chin K. Systematic Scoring Balloon Lesion Preparation for Drug-Coated Balloon Angioplasty in Clinical Routine: Results of the PASSWORD Observational Study. Adv Ther. 2020 May;37(5):2210-2223. doi: 10.1007/s12325-020-01320-2. Epub 2020 Apr 9. PubMed 32274746 ↗

Individual participant data

Plan to share: Undecided — Individual participant data may be made available to qualified researchers upon reasonable request after study completion and primary publication, subject to appropriate data use agreements and ethics committee approval.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 5, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07391033
Lead sponsor
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Feb 5, 2026

Study contacts

Filippo Luca Gurgoglione, MD, PhD
Contact
filippolucagurgoglione@gmail.com
+393312048150
Beatrice Barbano
Contact
segreteria@fondazioneric.org
Bharat Khialani, MD
principal investigator · Tan Tock Seng Hospital, National Healthcare Group, Singapore
Filippo Luca Gurgoglione, MD, PhD
principal investigator · Department of Cardiology, Parma University Hospital, Parma, Italy
Bernardo Cortese, MD
study chair · Fondazione Ricerca e Innovazione Cardiovascolare ETS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion